Follicular lymphoma trials in Spain

In Spain 22 Also abroad 189

21 of 22 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 15 November 2026. Ask the study team whether a trial fits you.

Phase 1Taking people
A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma
Where
Barcelona, Castello De La Plana, L'Hospitalet de Llobregat, Madrid, Málaga, Pozuelo de Alarcón, Valencia
Age
18 years and over
People
453 worldwide
Run by
Pfizer
See details and how to joinNCT03460977 · EU 2023-509179-18-00
Phase 1/2Taking people
A Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008)
Where
Badalona, Barcelona, Madrid, Málaga
Age
18 years and over
People
280 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT07519772 · EU 2025-523005-15-00
Phase 2/3Taking people
A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007)
Where
Badalona, Barcelona, Madrid, Málaga, Salamanca
Age
18 years and over
People
960 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT07634471 · EU 2025-522777-10-00
Phase 3Taking people
A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma
Where
A Coruña, Barakaldo, Barcelona, El Palmar, Granada, Madrid, Málaga, Murcia, Ourense, Oviedo, Palma, Pamplona, Pozuelo de Alarcón, Salamanca, Santander, Santiago de Compostela, Seville, Toledo, Valencia, Zaragoza
Age
18 years and over
People
822 worldwide
Run by
Regeneron Pharmaceuticals
See details and how to joinNCT06091254 · EU 2022-502660-20-00
Phase 3Active, not recruiting
A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone Lymphoma
Where
Barcelona, Granada, L'Hospitalet de Llobregat, Madrid, Oviedo, Palma, Pozuelo de Alarcón, Salamanca, Santander, Santiago de Compostela, Sevilla, Valencia
Age
18 years and over
People
580 worldwide
Run by
Regeneron Pharmaceuticals
See details and how to joinNCT06149286 · EU 2022-503092-28-00
Phase 1/2Active, not recruiting
An early study to investigate a new medicine for Subjects with Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL)
Where
Badalona, Barcelona, Madrid, Málaga, Salamanca
Age
18 years and over
People
204 worldwide
Run by
Celgene Corp.
See details and how to joinNCT03930953 · EU 2024-515690-10-00
Phase 1/2Taking people
Dose Escalation and Dose Expansion Study of MDX2003 in Patients With Different Types of Lymphoma
Where
Seville
Age
18 years and over
People
180 worldwide
Run by
ModeX Therapeutics, An OPKO Health Company
See details and how to joinNCT07249905
Phase 1Not yet taking people in Spain
A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
Where
Barcelona, Madrid
Age
18 years and over
People
215 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT07101328 · EU 2025-524180-20-00
Phase 1Not yet taking people in Spain
A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
Where
L'Hospitalet de Llobregat, Madrid
Age
18 years and over
People
460 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT07226843 · EU 2025-523601-16-00
Phase 1Taking people
IKS03 in Patients With Advanced B Cell Non-Hodgkin Lymphomas
Where
Badalona, Madrid, Salamanca
Age
18 years and over
People
140 worldwide
Run by
Iksuda Therapeutics Ltd.
See details and how to joinNCT05365659
Phase 1Not yet taking people in Spain
A Study of ARC-02 in B-cell NHL
Where
Barcelona, Cáceres, Madrid, Sevilla
Age
18 years and over
People
140 worldwide
Run by
Taiho Oncology, Inc.
See details and how to joinNCT07691606 · EU 2026-525606-35-00
Phase 3Not yet taking people in Spain
A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients
Where
Barcelona, Girona, Las Palmas De Gran Canaria, Madrid, Oviedo, Pamplona, Santander
Age
18 years to 130 years
People
1,018 worldwide
Run by
AstraZeneca
See details and how to joinNCT06549595 · EU 2023-510098-33-01
Phase 2Taking people
Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL
Where
Barcelona, Madrid, Pozuelo de Alarcón
Age
18 years and over
People
270 worldwide
Run by
AstraZeneca
See details and how to joinNCT06526793 · EU 2023-505789-27-00
Phase 1/2Taking people
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
Where
Barcelona, Madrid, Majadahonda, Valencia
Age
18 years and over
People
689 worldwide
Run by
BeOne Medicines
See details and how to joinNCT05006716 · EU 2022-502157-33-00
Phase 1/2Taking people
A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.
Where
Barcelona, L'Hospitalet de Llobregat, Madrid
Age
18 years and over
People
174 worldwide
Run by
AstraZeneca
See details and how to joinNCT06542250
Phase 1Suspended
Dose Determining Study of EXS73565 in Participants With Relapsed or Refractory B-Cell Malignancies
Where
Madrid, Pamplona
Age
18 years and over
People
85 worldwide
Run by
Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.
See details and how to joinNCT06980116 · EU 2024-516869-36-00
Phase 1Taking people
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
Where
Barcelona, Gijón, Madrid
Age
18 years and over
People
572 worldwide
Run by
Nurix Therapeutics, Inc.
See details and how to joinNCT05131022 · EU 2023-510541-25-00
Phase 2Taking people
Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients
Where
Barcelona, L'Hospitalet de Llobregat, Madrid, Murcia, Pamplona, Salamanca, Sevilla
Age
18 years to 70 years
People
213 worldwide
Run by
Miltenyi Biomedicine GmbH
See details and how to joinNCT04844866 · EU 2023-506270-13-00
Phase 3Taking people
A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)
Where
Granada, Madrid, Sabadell, Santander, Valencia
Age
18 years and over
People
400 worldwide
Run by
Celgene
See details and how to joinNCT06911502 · EU 2024-519152-82-00
Phase 1Taking people
Study of SGR-1505 in Mature B-Cell Neoplasms
Where
L'Hospitalet de Llobregat, Madrid, Pamplona, Pozuelo de Alarcón, Salamanca
Age
18 years and over
People
98 worldwide
Run by
Schrödinger, Inc.
See details and how to joinNCT05544019 · EU 2023-505204-34-00
Phase 1/2Taking people
IMMUNOTHERAPY WITH DIFFERENTIATED T CELLS, ADULTS, AUTOLOGOUS, FROM PERIPHERAL BLOOD, SELECTED BY CD62L EXPRESSION, EXPANDED AND TRANSDUCED (GENETICALLY MODIFIED) THROUGH A LENTIVIRAL VECTOR TO EXPRESS A CHIMERIC RECEPTOR WITH ANTI-CD19 SPECIFICITY ASSOCIATED WITH CO-STIMULATORY SEQUENCES 4-1-BB AND CD3Ζ IN PATIENTS WITH B-CELL NON-HODGKIN LYMPHOMA.
Where
Barcelona, Sevilla
Age
18 years and over
People
40
Run by
Fundacio Institut De Recerca De L'Hospital De La Santa Creu I Sant Pau
See details and how to join2024-519790-19-00